NCI-MATCH Searchable Treatment Arms Table

NCI-MATCH is a phase II precision medicine cancer trial with 39 treatment arms. See the table below. Each arm targets a unique gene abnormality known to drive cancer growth. Many of these driver mutations occur only rarely in patients, as shown by the posted frequency rates. These are the rates found in the first 6000 patients tested in this trial. Each arm has specific eligibility and exclusion criteria based on molecular characteristics of patients’ tumor genes, along with disease exclusions. For example, some arms exclude cancer types for which there is a standard treatment already available.

Below is a searchable list of all 39 treatment arms. Hover over any of the column headings and click the up/down arrows to sort. You can also search by keyword.

Download this information as a searchable spreadsheet.

All of this information is updated monthly.

Total accrual is 1,199 patients across all treatment arms as of 09/10/2022.

BRAF V600E or BRAF V600K mutations
(0.69% frequency)
Taflinar® (dabrafenib) and Mekinist™ (trametinib)Colorectal cancer, liver and hepatobiliary cancer (cholangiocarcinoma), melanoma, non-small cell lung cancer, ovarian cancer (low grade serous), or thyroid cancer

2nd Cohort

50 (7)10/2/2020OPEN

LAG-3 expression with microsatellite instability (MSI)
(1.51% frequency)

relatlimab + Opdivo® (nivolumab)Active melanomaZ1M35 (0)04/19/2021SUSPENDED

ALK translocations

(0.03% frequency)

Xalkori® (crizotinib) Non-small cell lung cancer, anaplastic large-cell lymphomaF35 (5)08/12/2015PUBLISHED

AKT mutations

(0.77% frequency)

capivasertibNoneY35 (35)05/31/2016PUBLISHED

BRAF fusions or non-V600E, non-V600K BRAF mutations

(0.80% frequency)

Mekinist™ (trametinib)NoneR35/3508/12/2015PUBLISHED

BRAF V600E or BRAF V600K mutations

(0.69% frequency)

Taflinar® (dabrafenib) and Mekinist™ (trametinib)Colorectal cancer, melanoma, thyroid cancer, non-small cell lung cancer

Initial Cohort

35 (35)08/12/2015PUBLISHED

FGFR pathway aberrations

(2.86% frequency)

AZD4547FGFR1-3 amplified squamous cell lung ca, gastric cancer, or gastro-esophageal junction cancerW70 (52)05/31/2016PUBLISHED

HER2 activating mutations

(1.04% frequency)

Gilotrif® (afatinib)Non-small cell lung cancerB70 (40)08/12/2015PUBLISHED

HER2 amplification

(1.49% frequency)

Kadcyla® (ado-trastuzumab emtansine)Breast cancer, gastric (stomach) cancer, or cancers where the food pipe (esophagus) meets the stomachQ35 (38)08/12/2015PUBLISHED

LAG-3 expression with MMR deficiency

(1.51% frequency)

Opdivo® (nivolumab)Colorectal cancer, locally advanced or metastatic urothelial carcinoma, unresectable or metastatic melanoma, metastatic non-small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, recurrent or metastatic squamous cancer of the head and neck, any other cancers for which nivolumab is approved or becomes approvedZ1D70 (47)05/31/2016PUBLISHED

NRAS mutations

(1.90% frequency)

binimetinibMelanomaZ1A70 (53)05/31/2016PUBLISHED

PIK3CA mutation with or without PTEN loss

(3.47% frequency)

copanlisibHER2-positive breast cancer, indolent non-Hodgkin’s lymphoma, or diffuse large B-cell lymphomaZ1F35 (35)06/20/2018PUBLISHED

PIK3CA mutation without RAS mutation or PTEN loss

(3.47% frequency)

taselisib Breast cancer or squamous cell lung cancer with PIK3CA mutation or lossI70 (70)02/23/2016PUBLISHED

ROS1 translocations

(0.05% frequency)

Xalkori® (crizotinib)Non-small cell lung cancer with ROS1 rearrangementsG35 (4)08/12/2015PUBLISHED
BRAF Non-V600 mutations
(0.80% frequency)
ulixertinibPrimary malignancy of the central nervous systemZ1L35 (35)07/25/2019PRESENTED

BRCA1 or BRCA2 mutations

(2.79% frequency)

adavosertibBreast cancerZ1I35 (33)03/13/2017PRESENTED

CCND1, 2, and 3 amplifications and Rb protein expression by immunohistochemistry

(0.84% frequency)

Ibrance® (palbociclib)Breast cancer, mantle cell lymphoma, or myelomaZ1B70 (40)05/31/2016PRESENTED

FGFR amplification

(1.86% frequency)

erdafitinibTransitional cell carcinoma of the bladder and /or urothelial tractK135 (35)06/20/2018PRESENTED

FGFR mutations or fusions

(1.00% frequency)

erdafitinibTransitional cell carcinoma of the bladder and /or urothelial tractK235 (35)06/20/2018PRESENTED

HER2 amplification

(1.49% frequency)

Herceptin® (trastuzumab) and Perjeta® (pertuzumab)Breast cancer, gastric (stomach) cancer, cancers where the food pipe (esophagus) meets the stomach, colorectal cancerJ35 (35)03/13/2017PRESENTED

NF2 loss

(0.69% frequency)

defactinib NoneU35 (35)08/12/2015PRESENTED

PTEN (deleterious) seq result and PTEN expression by immunohistochemistry

(1.75% frequency)

copanlisibIndolent NHL (Non-Hodgkin’s lymphoma) or DLBCL (diffuse large B cell lymphoma); HER2 positive breast cancerZ1H35 (35)06/20/2018PRESENTED

PTEN loss by immunohistochemistry (1.93% frequency) - Arm P


PTEN mutations or deletions, with PTEN expression on immunohistochemistry (1.75% frequency) - Arm N

GSK2636771NoneP & N

35 (35) P
35 (24) N

Smoothened (SMO) or patched 1 (PTCH1) mutations
(0.42% frequency)
Erivedge® (vismodegib)Basal cell skin cancerT35 (35)02/23/2016PRESENTED
AKT mutations
(0.77% frequency)
ipatasertib NoneZ1K35 (35)07/25/2019CLOSED
CDK4 or CDK6 amplification
(1.36% frequency)
Ibrance® (palbociclib)Breast cancer, mantle cell lymphoma, liposarcoma, or myelomaZ1C

49 (44)

Goal expanded from 35 to 49 in May 2020

cKIT mutations; PDGFRA or PDGFRB variants and fusions
(frequency 0.11%, 0.05%, and not available, respectively)
Sutent® (sunitinib malate) Gastrointestinal stromal tumors (GIST), renal cell carcinoma, or pancreatic neuroendocrine tumorsV35 (10)08/12/2015CLOSED
DDR2 mutations
(0.00% frequency)
Sprycel® (dasatinib)NoneX35 (0)02/23/2016CLOSED
EGFR-activating mutations
(0.05% frequency)
Gilotrif® (afatinib)Glioblastoma multiforme or lung cancer (small cell or non-small cell)A35 (19)08/12/2015CLOSED
EGFR T790M (with/without an activating mutation) or rare activating mutations of EGFR
(0.11% frequency)
osimertinibNoneE35 (19)08/12/2015CLOSED

GNAQ or GNA11 mutations

(0.16% frequency)

Mekinist™ (trametinib) Uveal melanomaS235 (4)02/23/2016CLOSED
MET amplification
(0.51% frequency)
Xalkori® (crizotinib)NoneC1

50 (44)

Goal expanded from 35 to 50 in May 2020

MET exon 14 deletion
(0.61% frequency)
Xalkori® (crizotinib)NoneC235 (20)05/31/2016CLOSED

mTOR, KEAP1 or NFE2L2 mutations

(frequency 0.31%, not available, and 1.25%, respectively)

sapanisertibNoneL35 (32)03/13/2017CLOSED

NF1 mutations

(1.77% frequency)

Mekinist™ (trametinib) Breast cancer S170 (50)02/23/2016CLOSED
NTRK fusions
(0.10% frequency)
larotrectinib NoneZ1E35 (16)03/13/2017CLOSED
PTEN mutations (except for a Copy Number=0) and PTEN negative by Immunohistochemistry
(1.93% frequency)
copanlisibIndolent non-Hodgkin’s lymphoma, diffuse large B cell lymphoma, or HER2-positive breast cancerZ1G35 (23)06/20/2018CLOSED
TSC1 or TSC2 mutations
(1.11% frequency)
sapanisertib NoneM

49 (49)

Goal expanded from 35 to 49 in May 2020

ECOG-ACRIN Cancer Research Group